Pharmacological approaches to prevent abdominal aortic aneurysm enlargement and rupture

Mark Rentschler, Bernard Timothy Baxter

Research output: Chapter in Book/Report/Conference proceedingConference contribution

19 Citations (Scopus)

Abstract

Current efforts to limit the mortality from abdominal aortic aneurysm (AAA) are dependent on detection and elective repair. Even by conservative estimates, there are more than 300,000 undetected AAAs in the United States, most of which are small and would not require immediate intervention. Current practice following detection of a small AAA includes education, risk factor management, and serial observation. This approach, based on the statistical probability of death from rupture compared to the morbidity and mortality of repair, can be unsettling to patients and lead to a decline in perceived quality of life. While the pathophysiology of AAA is not completely understood, observations from human tissues and animal studies have identified a number of potential targets for inhibiting aneurysm expansion. It is clear that the prominent inflammatory response identified in aneurysm tissue has a role in promoting aortic expansion. This inflammatory response is thought to account for increased expression of proteolytic enzymes. Recent work has suggested a unifying hypothesis centered on the MAP kinase family affecting both the regulation of matrix synthesis and the expression of proteolytic enzymes. The tetracycline antibiotics and antihypertensive medications that affect the angiotensin-converting enzyme system can inhibit proteolysis. There are adequate preliminary data to support a large prospective randomized trial of doxycycline to prevent aneurysm expansion.

Original languageEnglish (US)
Title of host publicationThe Abdominal Aortic Aneurysm
Subtitle of host publicationGenetics, Pathophysiology, and Molecular Biology
PublisherBlackwell Publishing Inc.
Pages39-46
Number of pages8
ISBN (Print)1573316571, 9781573316576
DOIs
StatePublished - Jan 1 2006

Publication series

NameAnnals of the New York Academy of Sciences
Volume1085
ISSN (Print)0077-8923
ISSN (Electronic)1749-6632

Fingerprint

Aortic Rupture
Abdominal Aortic Aneurysm
Aneurysm
Pharmacology
Repair
Peptide Hydrolases
Tissue
Proteolysis
Mortality
Doxycycline
Risk Management
Peptidyl-Dipeptidase A
Tetracycline
Antihypertensive Agents
Rupture
Animals
Phosphotransferases
Education
Quality of Life
Observation

Keywords

  • Aneurysm
  • Tetracycline

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

Rentschler, M., & Baxter, B. T. (2006). Pharmacological approaches to prevent abdominal aortic aneurysm enlargement and rupture. In The Abdominal Aortic Aneurysm: Genetics, Pathophysiology, and Molecular Biology (pp. 39-46). (Annals of the New York Academy of Sciences; Vol. 1085). Blackwell Publishing Inc.. https://doi.org/10.1196/annals.1383.003

Pharmacological approaches to prevent abdominal aortic aneurysm enlargement and rupture. / Rentschler, Mark; Baxter, Bernard Timothy.

The Abdominal Aortic Aneurysm: Genetics, Pathophysiology, and Molecular Biology. Blackwell Publishing Inc., 2006. p. 39-46 (Annals of the New York Academy of Sciences; Vol. 1085).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Rentschler, M & Baxter, BT 2006, Pharmacological approaches to prevent abdominal aortic aneurysm enlargement and rupture. in The Abdominal Aortic Aneurysm: Genetics, Pathophysiology, and Molecular Biology. Annals of the New York Academy of Sciences, vol. 1085, Blackwell Publishing Inc., pp. 39-46. https://doi.org/10.1196/annals.1383.003
Rentschler M, Baxter BT. Pharmacological approaches to prevent abdominal aortic aneurysm enlargement and rupture. In The Abdominal Aortic Aneurysm: Genetics, Pathophysiology, and Molecular Biology. Blackwell Publishing Inc. 2006. p. 39-46. (Annals of the New York Academy of Sciences). https://doi.org/10.1196/annals.1383.003
Rentschler, Mark ; Baxter, Bernard Timothy. / Pharmacological approaches to prevent abdominal aortic aneurysm enlargement and rupture. The Abdominal Aortic Aneurysm: Genetics, Pathophysiology, and Molecular Biology. Blackwell Publishing Inc., 2006. pp. 39-46 (Annals of the New York Academy of Sciences).
@inproceedings{4d9d4c1b5b5f4cc8bdf21f00eb6dd322,
title = "Pharmacological approaches to prevent abdominal aortic aneurysm enlargement and rupture",
abstract = "Current efforts to limit the mortality from abdominal aortic aneurysm (AAA) are dependent on detection and elective repair. Even by conservative estimates, there are more than 300,000 undetected AAAs in the United States, most of which are small and would not require immediate intervention. Current practice following detection of a small AAA includes education, risk factor management, and serial observation. This approach, based on the statistical probability of death from rupture compared to the morbidity and mortality of repair, can be unsettling to patients and lead to a decline in perceived quality of life. While the pathophysiology of AAA is not completely understood, observations from human tissues and animal studies have identified a number of potential targets for inhibiting aneurysm expansion. It is clear that the prominent inflammatory response identified in aneurysm tissue has a role in promoting aortic expansion. This inflammatory response is thought to account for increased expression of proteolytic enzymes. Recent work has suggested a unifying hypothesis centered on the MAP kinase family affecting both the regulation of matrix synthesis and the expression of proteolytic enzymes. The tetracycline antibiotics and antihypertensive medications that affect the angiotensin-converting enzyme system can inhibit proteolysis. There are adequate preliminary data to support a large prospective randomized trial of doxycycline to prevent aneurysm expansion.",
keywords = "Aneurysm, Tetracycline",
author = "Mark Rentschler and Baxter, {Bernard Timothy}",
year = "2006",
month = "1",
day = "1",
doi = "10.1196/annals.1383.003",
language = "English (US)",
isbn = "1573316571",
series = "Annals of the New York Academy of Sciences",
publisher = "Blackwell Publishing Inc.",
pages = "39--46",
booktitle = "The Abdominal Aortic Aneurysm",

}

TY - GEN

T1 - Pharmacological approaches to prevent abdominal aortic aneurysm enlargement and rupture

AU - Rentschler, Mark

AU - Baxter, Bernard Timothy

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Current efforts to limit the mortality from abdominal aortic aneurysm (AAA) are dependent on detection and elective repair. Even by conservative estimates, there are more than 300,000 undetected AAAs in the United States, most of which are small and would not require immediate intervention. Current practice following detection of a small AAA includes education, risk factor management, and serial observation. This approach, based on the statistical probability of death from rupture compared to the morbidity and mortality of repair, can be unsettling to patients and lead to a decline in perceived quality of life. While the pathophysiology of AAA is not completely understood, observations from human tissues and animal studies have identified a number of potential targets for inhibiting aneurysm expansion. It is clear that the prominent inflammatory response identified in aneurysm tissue has a role in promoting aortic expansion. This inflammatory response is thought to account for increased expression of proteolytic enzymes. Recent work has suggested a unifying hypothesis centered on the MAP kinase family affecting both the regulation of matrix synthesis and the expression of proteolytic enzymes. The tetracycline antibiotics and antihypertensive medications that affect the angiotensin-converting enzyme system can inhibit proteolysis. There are adequate preliminary data to support a large prospective randomized trial of doxycycline to prevent aneurysm expansion.

AB - Current efforts to limit the mortality from abdominal aortic aneurysm (AAA) are dependent on detection and elective repair. Even by conservative estimates, there are more than 300,000 undetected AAAs in the United States, most of which are small and would not require immediate intervention. Current practice following detection of a small AAA includes education, risk factor management, and serial observation. This approach, based on the statistical probability of death from rupture compared to the morbidity and mortality of repair, can be unsettling to patients and lead to a decline in perceived quality of life. While the pathophysiology of AAA is not completely understood, observations from human tissues and animal studies have identified a number of potential targets for inhibiting aneurysm expansion. It is clear that the prominent inflammatory response identified in aneurysm tissue has a role in promoting aortic expansion. This inflammatory response is thought to account for increased expression of proteolytic enzymes. Recent work has suggested a unifying hypothesis centered on the MAP kinase family affecting both the regulation of matrix synthesis and the expression of proteolytic enzymes. The tetracycline antibiotics and antihypertensive medications that affect the angiotensin-converting enzyme system can inhibit proteolysis. There are adequate preliminary data to support a large prospective randomized trial of doxycycline to prevent aneurysm expansion.

KW - Aneurysm

KW - Tetracycline

UR - http://www.scopus.com/inward/record.url?scp=34147194346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147194346&partnerID=8YFLogxK

U2 - 10.1196/annals.1383.003

DO - 10.1196/annals.1383.003

M3 - Conference contribution

SN - 1573316571

SN - 9781573316576

T3 - Annals of the New York Academy of Sciences

SP - 39

EP - 46

BT - The Abdominal Aortic Aneurysm

PB - Blackwell Publishing Inc.

ER -